Impact of Invasive Mechanical Ventilation on the Lung Microbiome.

Publication date: Jul 01, 2025

The lung microbiota is integral to maintaining microenvironmental homeostasis, influencing immune regulation, host defense against pathogens, and overall respiratory health. The dynamic interplay among the lung microbiota emphasizes their significance in shaping the respiratory milieu and potential impact on diverse pulmonary affections. This investigation aimed to identify the effects of invasive mechanical ventilation on the lung microbiome. Materials and Methods: A systematic review was conducted with registration number CRD42023461618, based on a search of PubMed, SCOPUS, and Web of Science databases, in line with the PRISMA guidelines. To achieve this, “(mechanical ventilation) AND (microbiota)” was used as the search term, replicable across all databases. The closing date of the search was 12 March 2025, and the evidence was scored using the MINORS scale. Results: A total of 16 studies were included, with patients aged 13. 6 months to 76 years, predominantly male (64. 2%). Common ICU admission diagnoses requiring invasive mechanical ventilation (IMV) included pneumonia, acute respiratory failure, and COVID-19. IMV was associated with reduced lung microbiota diversity and an increased prevalence of pathogenic bacteria, including Prevotella, Streptococcus, Staphylococcus, Pseudomonas, and Acinetobacter. The most frequently used antibiotics were cephalosporins, aminoglycosides, and penicillins. IMV-induced pulmonary dysbiosis correlated with higher infection risk and mortality, particularly in pneumonia and COVID-19 cases. Factors such as antimicrobial therapy, enteral nutrition, and systemic inflammation contributed to these alterations. Conclusions: Invasive mechanical ventilation has been associated with the development of alterations in the respiratory microbiome, resulting in reduced diversity of lung microorganisms.

Open Access PDF

Concepts Keywords
Antimicrobial artificial respiration
Crd42023461618 COVID-19
Homeostasis dysbiosis
Pulmonary Humans
Staphylococcus humans
Lung
mechanical ventilation
Microbiota
microbiota
Respiration, Artificial
SARS-CoV-2

Semantics

Type Source Name
disease IDO host
disease MESH pneumonia
disease MESH respiratory failure
disease MESH COVID-19
disease IDO bacteria
disease MESH dysbiosis
disease MESH infection
disease MESH inflammation
drug DRUGBANK Coenzyme M
drug DRUGBANK Oxygen
drug DRUGBANK Carbon dioxide
disease IDO production
pathway REACTOME Antimicrobial peptides
drug DRUGBANK Diphenylpyraline
disease IDO pathogen
disease IDO immune response
disease MESH acute respiratory distress syndrome
disease MESH hospital acquired pneumonia
disease IDO intervention
disease MESH hypoxemia
disease MESH lung injury
disease MESH respiratory infections
disease MESH respiratory diseases
disease MESH etiology
disease MESH critically ill
drug DRUGBANK Methionine
disease MESH pulmonary fibrosis
drug DRUGBANK Trestolone
disease IDO quality
disease MESH Aspiration pneumonia
disease MESH Sepsis
disease MESH lung diseases
disease MESH clinical importance
drug DRUGBANK Isoxaflutole
drug DRUGBANK Cefotaxime
drug DRUGBANK Ceftriaxone
drug DRUGBANK Cefoperazone
drug DRUGBANK Sulbactam
drug DRUGBANK Ceftazidime
drug DRUGBANK Cefepime
drug DRUGBANK Amikacin
drug DRUGBANK Gentamicin
drug DRUGBANK Oxacillin
drug DRUGBANK Ciprofloxacin
drug DRUGBANK Levofloxacin
drug DRUGBANK Linezolid
drug DRUGBANK Vancomycin
drug DRUGBANK Sulfamethoxazole
drug DRUGBANK Imipenem
drug DRUGBANK Meropenem
drug DRUGBANK Tetracycline
drug DRUGBANK Tigecycline
drug DRUGBANK Fosfomycin
drug DRUGBANK Metronidazole
drug DRUGBANK Trimethoprim
drug DRUGBANK Colistin
drug DRUGBANK Amphotericin B
disease IDO susceptibility
disease MESH posture
disease MESH complications
pathway REACTOME Immune System
disease IDO process
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease IDO virulence
drug DRUGBANK Guanosine

Original Article

(Visited 2 times, 1 visits today)